Search

Displaying results 2551 - 2560 of 8171 in total
  1. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). … By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  2. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment

  3. Drug

    DA-697b

    go.drugbank.com/drugs/DB06001
    Experimental

    DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.

  4. Drug

    Poa pratensis pollen

    go.drugbank.com/drugs/DB10366
    Approved

    Poa pratensis pollen is the pollen of the Poa pratensis plant. Poa pratensis pollen is mainly used in allergenic testing.

  5. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Colestilan chloride

    go.drugbank.com/drugs/DB11634
    ApprovedWithdrawn

    Colestilan is an ingredient in the EMA-withdrawn product BindRen.

  7. Drug

    Nomegestrol

    go.drugbank.com/drugs/DB11636
    Approved

    Nomegestrol is an ingredient in the EMA-authorised product Zoely.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Siagoside

    go.drugbank.com/drugs/DB12351
    Investigational

    Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. Sygen appears to be beneficial in patients with severe spinal cord injury.

  9. Drug

    Metronidazole

    go.drugbank.com/drugs/DB00916
    ApprovedInvestigational

    [A181036,A181039] Metronidazole has been used as an antibiotic for several decades[L7429], with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  10. Drug

    Alosetron

    go.drugbank.com/drugs/DB00969
    ApprovedWithdrawn

    Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. … Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors